betadex and regorafenib

betadex has been researched along with regorafenib* in 2 studies

Other Studies

2 other study(ies) available for betadex and regorafenib

ArticleYear
[Preparation, characterization and antitumor of cyclodextrin inclusion of an anti-cancer drug regorafenib].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2017, 03-25, Volume: 46, Issue:2

    Topics: Antineoplastic Agents; beta-Cyclodextrins; Cell Line, Tumor; Cell Survival; Humans; Phenylurea Compounds; Pyridines; Solubility; Spectroscopy, Fourier Transform Infrared

2017
Evaluation of molecular chaperone drug function: Regorafenib and β-cyclodextrins.
    Colloids and surfaces. B, Biointerfaces, 2017, May-01, Volume: 153

    Regorafenib (RG) was an oral multi-kinase inhibitor with poor water solubility. In order to enhance the drug's solubility, dissolution and bioavailability, the binary molecular chaperone drug between RG and β-cyclodetrin (β-CD) had prepared by co-crystallization. The structure of RG-β-CD was characterized by thermal analysis, powder X-ray diffraction, infrared spectroscopy and nuclear magnetic resonance. Phase-solubility study revealed the higher solubility and complexing ability of β-CDwith RG.The solubility and dissolution of RG-β-CD was significantly enhanced in pH 1.2 medium, pH 6.8 PBS buffer solution and distilled water compared to RG. In vivo distribution and antitumor studies revealed that the bioavailability of RG-β-CD was increased when β-CD mated with RG. Therefore, these findings could provide a suitable pharmaceutical dosage to enhanced therapeutic activity.

    Topics: Administration, Oral; Animals; Antineoplastic Agents; beta-Cyclodextrins; Biological Availability; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crystallization; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Chaperones; Molecular Structure; Neoplasms, Experimental; Phenylurea Compounds; Pyridines; Solubility; Structure-Activity Relationship

2017